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As a novel strategy to remove β-lactam antibiotic residues from fish tissues, utilization of β-lactamase, enzyme that
normally degrades β-lactam structure-containing drugs, was explored. The enzyme (TEM-52) selectively degraded
β-lactam antibiotics but was completely inactive against tetracycline-, quinolone-, macrolide-, or aminoglycoside-
structured antibacterials. After simultaneous administration of the enzyme with cefazolin (a β-lactam antibiotic) to
the carp, significantly lowered tissue cefazolin levels were observed. It was confirmed that the enzyme successfully
reached the general circulation after intraperitoneal administration, as the carp serum obtained after enzyme
injection could also degrade cefazolin ex vivo. These results suggest that antibiotics-degrading enzymes can be
good candidates for antibiotic residue depuration.
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Concerns have risen over the presence of antimicrobial
residues in food fishes because the contaminants can
cause human pathogenic bacteria to develop resistance
to therapeutically valuable antimicrobials (Cabello, 2006).
Development of antibacterial resistance will then require
higher doses of the same agent, or more potent drugs for
efficacious treatment of bacterial pathogens. Of several
known mechanisms for resistance development, deg-
radation of antimicrobial agents is regarded as the most
frequent one (De Pascale and Wright 2010).
Soon after the introduction of β-lactam antibiotics
such as penicillins and cephalaosporins into clinical
use, bacterial resistance to these drugs were reported
(Abraham and Chain, 1988). Those bacteria have been
found to harbor plasmid-borne genes producing en-
zymes which can catalyze a few β-lactam antibiotics
nullifying the efficacy of such drugs (Matagne et al.
1999). However, the efficacy has become increasingly* Correspondence: khpark@kunsan.ac.kr
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broader range of β-lactam antibiotics compared with
previous enzymes (Livermore 1995). Those enzymes are
called extended-spectrum β-lactamase (ESBL) and they
are usually represented by TEM-52.
If β-lactamase can catalyze β-lactam antibiotics in fish
tissues, it could be useful to remove residual antibiotics
remaining after use to food fish species. To test this pos-
sibility, we assessed the catalytic activity in vitro of puri-
fied TEM-52 enzymes obtained by recombinant DNA
techniques, followed by an in vivo activity test in carp
after administration of cefazolin, a β-lactam antibiotic.Methods
β-Lactamase enzyme preparations
The gene for TEM-52 was obtained from a Korean clinical
isolate after necessary cloning processes (Pai et al., 1999).
Its sequence was confirmed to match 100% by query
coverage tests with those of extended-spectrum enzymes
reported from Salmonella enterica subspp. enterica
serovar Typhimurium (gb|AY883411.1|) and Klebsiella
pneumoniae (emb|Y13612.1). This gene was used to
build a recombinant plasmid and inserted into E. colile is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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plex media. When the culture reached the density of ca.
0.7 optical density at 650 nm, cells were harvested by
centrifugation (×13,000g, 10 min, 3 °C). Cells were
disrupted by sonication and the lysate was processed
for purification purposes with Q-Sepharose FF column
chromatography after refolding steps. The refolding
process was composed of decreasingly stepwise dilu-
tions at 8, 2, 1, and 0.4 M in denaturant urea. The
TEM-52 enzyme was eluted in 20 mM Tris buffer
(pH 7.0) and adjusted to contain 500 mU/ml β-lactamase
activity when assayed for 5 min using nitrocefin (50 μg/
ml, Oxoid, Basingstoke, UK) as the substrate (O’Callaghan
et al., 1972). The final purified TEM-52 enzyme is known
to have a molecular mass of 28 KDa (Perilli et al., 2002).
In vitro degradation activities against various
antimicrobials
Degradation activity of TEM-52 against various classes of
antimicrobials was assessed incubating the β-lactamase
enzyme solution (25 mU/ml) with various antimicrobials.
Ten different antimicrobials (cefotaxime-Na, cefazolin-
Na, penicillin-G-K salt, amoxicillin, pivampicillin,
oxytetracycline-HCl, ciprofloxacin, erythromycin, josamy-
cin, and streptomycin) were incubated with TEM-52 in
50 mM sodium phosphate buffer (pH 7.0) for 30 min at
25 °C, and then followed by bioassay for semi-quantitative
analysis of remaining drug levels. These antimicrobials
were obtained from Sigma (St. Louis, MO, USA) except
pivampicillin (Dong-Hwa Pharmaceuticals, Seoul, Korea)
and josamycin (Wako Chemicals, Japan). Paper disks
(8 mm diameter, Advantec Toyo, Dublin, CA, USA) were
soaked with 50 μl of incubated enzyme-antimicrobial mix-
tures and placed on top of BHI agar in Petri dishes
streaked with Staphylococcus epidermidis ATCC10145
(precultured in BHI to 1.8 × 107 CFU/ml). The dishes
were incubated at 36 °C for 12 h, and inhibitory zones be-
yond the disk areas were measured.
In vivo and ex vivo degradation activities against cefazolin
Of several β-lactam antibiotics, cefazolin was selected as
the model antibiotic because of the simplicity in chem-
ical analysis for both in vivo and ex vivo studies. To as-
sess degradation activity of TEM-52 more quantitatively
than the above in vitro study, cefazolin was incubated
with TEM-52 (25 mU/ml in 50 mM phosphate buffer,
pH 7.0) for 30 min and remaining concentration of cefa-
zolin was chemically analyzed with a high-performance
liquid chromatography (HPLC) method.
The HPLC-UV method for cefazolin analysis (Nadai
et al., 1993) was composed of a Waters 2690 separation
module and Waters 2487 dual wavelength UV-visible de-
tector at 274 nm (Waters, Milford, MA, USA). Samples
were injected into a C18 reverse-phase HPLC column(250 × 4.6 mm, 5 μm particle size, Shiseido, Japan) at
10–50 μl range and eluted with a mobile phase com-
posed of 30 mM sodium phosphate buffer (pH 5.0) and
methanol (88:12 ratio). Flow rate of the mobile phase
was 1.2 ml/min.
For in vivo cefazolin degradation experiment, common
carp Cyprinus carpio weighing 40–100 g maintained at
23 °C were used. Cefazolin (sodium salt, Sigma) was dis-
solved in sterile saline and administered intramuscularly
(im) around the lateral line to render doses of 10 and
30 mg/kg of drug base. TEM-52 enzyme was immedi-
ately injected into the peritoneal cavity at 75 mU/100 g
body weight. This intraperitoneal (ip) injection volume
was 150 μl/100 g and an equivalent volume of saline
was also administered to control fish. One hour after
TEM-52 injections, fish were anesthetized with MS-222
(Sigma) and blood was sampled for cefazolin analysis
through the caudal vessels. Serum was subsequently
obtained following centrifugation at ×3600g for 20 min
under refrigeration (3 °C). Liver and muscle were also
isolated for cefazolin analyses. Serum and fish tissues
were mixed with HPLC mobile phase in tenfold vol-
umes and vigorously vortex-shaken before filtering
through membrane filters, and finally injected into the
HPLC column. This method led to an almost complete
cefazolin recovery (>90%, n = 3). With cefazolin-spiked
liver and muscle tissues (10, 20, 50, 100, and 200 ng/g),
linearity of the standard curve was confirmed (r2 =
0.967). The limits of detection (LOD) and quantifica-
tion (LOQ) were 10 and 30 ng/g, respectively.
In some fish, TEM-52 was administered into the peri-
toneal cavity (ip) at 75 mU/100 g to naive carp, and
serum was obtained 1 h later to assess ex vivo degrad-
ation activity against cefazolin. All experiments using
carp were performed in accordance with the guidelines
approved by the Institutional Animal Care and Use
Committee, Kunsan National University, Korea.
Statistics
Data were expressed as mean ± S.D. Statistical significance
was examined with unpaired t tests at the significant level
of p < 0.05.
Results and discussion
Table 1 shows in vitro enzymatic activity of TEM-52 to
degrade different classes of antibacterial agents. TEM-52
is a wide spectrum β-lactamase obtained from E. coli
through recombinant DNA technique. The enzyme prep-
aration reduced antibacterial activity of β-lactam antibi-
otics without effects on drugs of other classes, indicating
highly selective degradation activity toward β-lactams.
Other classes of antibacterials, i.e., tetracycline, quinolone,
macrolide, and aminoglycoside, were not influenced at all.
These data reflect that the enzyme preparation contains
Table 1 Bioassay of degradation activity of TEM-52 enzyme against various classes of antimicrobials
Class Antimicrobials Inhibition zone (mm, mean ± SD)
Control drug disk TEM-52-treated drug disk
β-Lactam Cefotaxime 9.3 ± 0.6 0.0 ± 0.0
Cefazolin 6.0 ± 1.7 2.3 ± 1.2
Penicillin G 8.0 ± 0.6 0.0 ± 0.0
Amoxicillin 8.7 ± 0.6 0.0 ± 0.0
Pivampicillin 7.3 ± 0.6 0.0 ± 0.0
Tetracycline Oxytetracycline 9.8 ± 0.9 9.7 ± 0.6
Quinolone Ciprofloxacin 8.2 ± 0.0 8.0 ± 0.4
Macrolide Erythromycin 10.0 ± 1.0 10.0 ± 2.0
Josamycin 8.6 ± 0.6 8.7 ± 0.5
Aminoglycoside Streptomycin 8.5 ± 0.4 8.7 ± 0.6
Concentrations of antimicrobials in incubation were adjusted to produce 6–11 mm clear zones beyond the disk areas (0.5–500 μg/disk)
Triplicate determinations
Fig. 1 In vivo and ex vivo cefazolin degradation activity of TEM-52 in carp. a–c In vivo cefazolin changes in serum (a), liver, (b) and muscle (c)
following intraperitoneal injection of TEM-52, N = 5–10; filled bar, control carp; shaded bar, TEM-52-injected carp (d) ex vivo cefazolin changes
when TEM-52-injected carp serum were incubated with cefazolin, N = 5; filled bar, without enzyme; shaded bar, incubated with TEM-52 itself or
TEM-52-injected carp serum. *p < 0.05 with unpaired t tests when compared to control groups
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cephalosporins, and penicillins (Bush et al., 1995; Pai
et al., 1999; Poyart et al., 1998; Shahada et al., 2010),
without any activity on other antibacterials.
Of the five β-lactam antibiotics examined with the
in vitro bioassay, cefazolin was chosen for in vivo studies
mostly because the procedures for HPLC analysis are
quite simple. The results obtained after simultaneous ad-
ministration of TEM-52 and cefazolin to carp are dem-
onstrated in Fig. 1. In all three tissue samples examined,
the levels of cefazolin were significantly lower in TEM-
52 co-administered fish compared with the cefazolin-
alone group. With cefazolin doses 10 and 30 mg/kg, and
regardless of tissues, the degree of reduction was ∼50%
(Fig. 1a–c). In this in vivo experiment, TEM-52 was
administered into the peritoneal cavity whereas cefazolin
into the muscle. These results therefore indicate that β-
lactamase activity included in TEM-52 and the β-lactam
antibiotic cefazolin could come into direct contact in the
fish body leading to cefazolin degradation. These results
thus clearly demonstrate that TEM-52 is active not only
in vitro system but also in the fish body, i.e., in vivo fol-
lowing injections.
It was additionally checked whether TEM-52 was
actually present in carp serum after intraperitoneal injec-
tion to the fish. For this, TEM-52 was injected and
serum was sampled 1 h later for ex vivo degradation
tests. After incubation of TEM-52-pretreated carp serum
with cefazolin ex vivo, a significant reduction (p < 0.05)
in cefazolin residue was observed (Fig. 1d, Carp serum
columns). In a parallel test, it was observed that if a
higher reduction of cefazolin concentration occurred,
cefazolin was incubated directly with TEM-52 in the
presence of naive serum (Fig. 1d, TEN-52 columns).
Although it is difficult to compare directly because these
two test conditions were not identical, a significant
portion of intact TEM-52 enzymes seemed to reach in
serum when blood was taken (1 h post-injection).
Because TEM-52 was active for cefazolin degradation
in carp, it can be deduced that the administered enzyme
must have been sufficiently absorbed from the peritoneal
cavity. It is not well described in fishes whether there is
an inhibiting barrier to proteins injected into the peri-
toneal cavity. However, the fact that peptides are system-
ically active following intraperitoneal injection in fishes
(Hong and Secombe, 2009; Murashita et al., 2010) sug-
gests a loose barrier within the peritoneum in fishes. In
rats too, absorption of proteins from the peritoneum is
comparable to that of isotonic solution (Flessner, 2005).
Conclusions
In summary, this study is the first attempt to seek a
utilization of sorts of antibiotics degradation enzymes to
depurate drug residues in animals. We observed thatTEM-52, an enzyme active against a broad range of β-
lactam antibiotics, can be a novel tool to remove resi-
dues from drug-treated fish bodies. It may be needed to
expand tests against other β-lactam antibiotics and also
in different fish species. There has not been any attempt
in idea similar to this up to now. Various aspects of
studies need to be carried out in order to establish prac-
tical usefulness. Safety of the test enzyme to humans is
not known at all, for example.
Conclusively, however, a similar strategy will also be
applicable to various classes of antimicrobials to which
antibiotic-degrading enzymes have been reported.
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